Analysts Set Qiagen N.V. (NYSE:QGEN) PT at $43.15

Qiagen N.V. (NYSE:QGEN) has received an average rating of “Hold” from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $43.3417.

A number of research firms recently weighed in on QGEN. Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Tuesday, July 14th. JPMorgan Chase & Co. dropped their target price on Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Citigroup reiterated a “hold” rating on shares of Qiagen in a research report on Monday, May 18th. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. Finally, TD Cowen reiterated a “hold” rating on shares of Qiagen in a research note on Wednesday.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $41.19 on Monday. The company has a quick ratio of 2.57, a current ratio of 3.21 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $8.49 billion, a PE ratio of 21.51, a P/E/G ratio of 4.11 and a beta of 0.64. Qiagen has a twelve month low of $32.53 and a twelve month high of $57.81. The company has a 50-day moving average price of $37.34 and a two-hundred day moving average price of $42.33.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.54 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.54. The company had revenue of $492.32 million for the quarter, compared to analyst estimates of $496.15 million. Qiagen had a net margin of 19.16% and a return on equity of 14.40%. During the same quarter in the previous year, the firm posted $0.56 earnings per share. Equities analysts forecast that Qiagen will post 2.43 EPS for the current year.

Qiagen Increases Dividend

The business also recently announced an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were issued a dividend of $0.35 per share. This represents a yield of 90.0%. The ex-dividend date of this dividend was Tuesday, July 7th. This is a boost from Qiagen’s previous annual dividend of $0.26. Qiagen’s payout ratio is presently 18.32%.

Institutional Investors Weigh In On Qiagen

Hedge funds and other institutional investors have recently modified their holdings of the stock. Danske Bank A S bought a new position in shares of Qiagen in the third quarter valued at approximately $36,000. Manchester Capital Management LLC purchased a new stake in Qiagen in the 4th quarter worth approximately $42,000. Hilltop National Bank purchased a new stake in Qiagen in the 2nd quarter worth approximately $50,000. Global Retirement Partners LLC boosted its holdings in Qiagen by 279.9% in the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after purchasing an additional 851 shares during the period. Finally, Allworth Financial LP boosted its holdings in Qiagen by 23.2% in the 3rd quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after purchasing an additional 256 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.